Back to Newsroom

Sigilon Therapeutics Introduces Scientific Advisory Board for Guiding Development of Afibromer™ Living Therapeutics

CAMBRIDGE, Mass.Oct. 16, 2017 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the formation of a scientific advisory board (SAB) to guide the development of therapeutics based on proprietary engineered cell lines and Afibromer™ biomaterials technology.